酪氨酸激酶抑制剂对QT间期的影响及临床意义研究进展

酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）是一种新型的抗肿瘤药物，近年来被广泛应用于临床，已有药物临床试验表明该类药物对多种癌症有良好的治疗效果，其对QT间期影响也被大量报道，但每种药物对QT间期的影响程度不尽相同，因此，每种TKI药物在使用时需要注意及监测的指标也不尽相同。其中一些能引起严重QT间期延长甚至猝死的TKI，我们更需要根据患者的QT间期及时调整药物剂量。本文通过阅读国内外关于药物临床试验的相关文献及FDA药物说明书等，对目前已上市的TKI的临床药物研究中针对QT间期的实验以及用药中的剂量调整等需要注意的事项进行总结分析，通过对既往实验结果的总结，更好地了解对该类药物的作用风险，对临床用药起到一定的指导作用。

Advances in effects of tyrosine kinase inhibitors on QT interval and its clinical significance

Tyrosine kinase inhibitors (TKIs) are typically used as novel anti-tumor drugs, which have been widely applied to clinical treatments in recent years. Clinical trials have demonstrated that these drugs are effective in the treatment of various cancers. TKIs have also been reported to affect the QT interval, but the effects are not the same in different drug treatments. Therefore, each TKI has different warnings,precautions, and monitoring indicator. Some of TKIs can cause severe QT interval prolongation and even sudden death, so we need to adjust the dose according to the individual patient's QT interval. In this paper, we reviewed the related literature and the FDA drug instructions, and analyzed the clinical trials focusing the effects of listed TKIs on QT interval and dosage adjustment. The risks of such drugs have been better understood via the summary of the previous experimental results, and it would play a guiding role to TKIs clinical treatments.